Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

An interview with Professor Monaco on being an Oxford-Harrington Scholar and how her research will change cardiovascular healthcare.

Oxford-Harrington Scholar Professor Claudia Monaco talked to OxfordMedSci News on the benefits of the Oxford-Harrington Scholarship Programme and how the Harrington Discovery Institute’s drug development experts are helping her think translationally about her research in order to move her cardiovascular inflammation research from the lab to the clinic.

Her lab at the Kennedy Institute studies inflammation in metabolic diseases such as atherosclerosis by looking at immune cells in blood vessel walls. Atherosclerosis is one of the main causes of cardiovascular disease and a major cause of death worldwide. 

You can read the full interview here.

Similar stories

The Kennedy Institute Student Symposium returns for its 5th year

A two-day student symposium returned to the Kennedy Institute bringing together students and peers from across the department to discuss their latest research.

Researchers from the Kennedy Institute awarded MRC funding

Tonia Vincent, Jelena Bezbradica and Alex Clarke have been awarded funding grants by the Medical Research Council (MRC) for different projects.

The Kennedy Institute completes its roof extension

Building work at the Kennedy Institute of Rheumatology has finished, providing a new third floor that houses additional meeting and collaboration space for data science and offices for the management of clinical trials.

Major ERC funding awarded to Professor Michael Dustin

Professor Michael Dustin and an international team of collaborators have been awarded a €10M grant from the European Research Council (ERC) to develop a new biotechnology around supramolecular attack particles (SMAPs) engineered to kill cancer cells.

Drug may boost vaccine responses in older adults

A preliminary study shows that a drug which helps immune cells self-clean may improve vaccine protection in older adults

£3M invested to drive forward early translation through five new Oxford-Bristol Myers Squibb Fellowships

Five new Oxford-Bristol Myers Squibb Fellowships representing an investment of £3M have been announced. The fellowships (formerly Oxford-Celgene) will support postdoctoral researchers and clinicians across five departments within the Medical Sciences Division and the Mathematical, Physical and Life Sciences Division, providing an opportunity for them to gain exposure to the field of commercial drug discovery and development.